SCHEMBL23798124

SCHEMBL23798124

COc1cc(-c2cn(C)c(=O)c3cc(F)ccc23)cc(Cl)c1C=O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 14/20 0.57
BRD9 Q9H8M2 3/20 0.43
BRD7 Q9NPI1 3/20 0.43
BRD2 P25440 1/20 0.43
SCN9A Q15858 2/20 0.41
TAF1 P21675 1/20 0.40
TGFBR1 P36897 1/20 0.40
BRPF1 P55201 1/20 0.40
ACVR1 Q04771 1/20 0.40
BPTF Q12830 1/20 0.40
TAF1L Q8IZX4 1/20 0.40
CREBBP Q92793 1/20 0.40
CECR2 Q9BXF3 1/20 0.40
BAZ2B Q9UIF8 1/20 0.40
ATAD2B Q9ULI0 1/20 0.40
PARG Q86W56 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30032371 1.00 BRD4 (0.57) BRD4BRD9BRD7BRD2SCN9A
SCHEMBL23783384 0.89 BRD4 (0.58) BRD4BRD9BRD7BRD2TAF1
SCHEMBL25846135 0.86 BRD4 (0.58) BRD4BRD9BRD7BRD2
SCHEMBL30032468 0.83 BRD4 (0.47) BRD4BRD9BRD7BRD2SCN9A
SCHEMBL23783301 0.83 BRD4 (0.47) BRD4BRD9BRD7BRD2SCN9A
SCHEMBL23783145 0.82 BRD4 (0.55) BRD4BRD9BRD7BRD2SCN9A
SCHEMBL30032016 0.82 BRD4 (0.55) BRD4BRD9BRD7BRD2SCN9A
SCHEMBL23783036 0.82 BRD9 (0.61) BRD4BRD9BRD7BRD2TAF1
SCHEMBL23783055 0.79 BRD4 (0.56) BRD4BRD9BRD7BRD2TAF1
SCHEMBL22291376 0.78 ERN1 (0.50) BRD4BRD9BRD7BRD2TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-02 US disclosed
CN-115279370-A Compounds for targeted degradation of BRD9 C4医药公司 2022-11-01 CN disclosed
WO-2021178920-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2021-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 BRD4 30/4885BRD9 1/4885BRD7 8/4885
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD4 17/4885BRD9 1/4885BRD7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.